SCHEMBL19024770

SCHEMBL19024770

Clc1cnc(NC2CCC(NCC3CCCNC3)CC2)nc1-c1c[nH]c2ccccc12

nearest known ligand 0.76

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
▸ CCNK O75909 18/20 0.76
▸ CDK12 Q9NYV4 18/20 0.76
▸ CCNT1 O60563 16/20 0.76
▸ CDK9 P50750 16/20 0.76
▸ CDK7 P50613 15/20 0.76
▸ CCNH P51946 14/20 0.76
▸ CCNE1 P24864 13/20 0.76
▸ CDK2 P24941 13/20 0.76
▸ CRBN Q96SW2 1/20 0.76
▸ MNAT1 P51948 13/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17150427 1.00 CCNK (0.76) CCNKCDK12CCNT1CDK9CDK7
SCHEMBL19054693 1.00 CCNK (0.76) CCNKCDK12CCNT1CDK9CDK7
Hydrochloric Acid SCHEMBL19024517 0.99 CCNK (0.75) CCNKCDK12CCNT1CDK9CDK7
SCHEMBL17150629 0.90 CDK2 (0.67) CCNKCDK12CCNT1CDK9CDK7
SCHEMBL20416312 0.90 CDK2 (0.67) CCNKCDK12CCNT1CDK9CDK7
SCHEMBL24839342 0.86 CCNT1 (1.00) CCNKCDK12CCNT1CDK9CDK7
SCHEMBL20190942 0.86 CCNT1 (1.00) CCNKCDK12CCNT1CDK9CDK7
SCHEMBL20190945 0.86 CCNT1 (1.00) CCNKCDK12CCNT1CDK9CDK7
SCHEMBL29613489 0.86 CCNT1 (1.00) CCNKCDK12CCNT1CDK9CDK7
SCHEMBL19024524 0.86 CDK7 (0.67) CCNKCDK12CCNT1CDK9CDK7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3489232-A2 INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) Syros Pharmaceuticals, Inc. (US) 2019-05-29 — — EP disclosed
EP-3489232-A2 INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) Syros Pharmaceuticals, Inc. (US) 2019-05-29 — — EP disclosed
US-20180319772-A1 INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) OXFORD FINANCE LLC, AS COLLATERAL AGENT 2018-11-08 — — US disclosed
US-10106526-B2 Inhibitors of cyclin-dependent kinase 7 (CDK7) SYROS PHARMACEUTICALS, INC. (US) 2018-10-23 — — US disclosed
US-10059690-B2 Inhibitors of cyclin-dependent kinase 7 (CDK7) SYROS PHARMACEUTICALS, INC. (US) 2018-08-28 — — US disclosed
US-20180208578-A1 INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) OXFORD FINANCE LLC, AS COLLATERAL AGENT 2018-07-26 — — US disclosed
US-20180208578-A1 INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) OXFORD FINANCE LLC, AS COLLATERAL AGENT 2018-07-26 — — US disclosed
US-20170183355-A1 INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) OXFORD FINANCE LLC, AS COLLATERAL AGENT 2017-06-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10059690-B2 Inhibitors of cyclin-dependent kinase 7 (CDK7) CDK7, CDK3, CDK9 CCNK 8/4885CDK12 24/4885CCNT1 34/4885
US-10106526-B2 Inhibitors of cyclin-dependent kinase 7 (CDK7) CDK7, CDK3, CDK9 CCNK 8/4885CDK12 24/4885CCNT1 34/4885
US-20180208578-A1 INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) CDK7, CDK3, CDK9 CCNK 8/4885CDK12 24/4885CCNT1 34/4885
US-20180319772-A1 INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) CDK7, CDK3, CDK9 CCNK 8/4885CDK12 24/4885CCNT1 34/4885
US-20170183355-A1 INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) CDK7, CDK3, CDK9 CCNK 8/4885CDK12 24/4885CCNT1 34/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback